Maxion Therapeutics
Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.
Maxion Therapeutics has raised €83M across 3 funding rounds from 8 investors, most recently a Series A round in Mar 2025. Based in Cambridge, UK; active in Healthtech. Data as of 28 Oct 2026.
Cambridge, UKwww.maxion.co.uk ↗
Total raised
€83M
€82,932,781
Funding rounds
3
Investors
8
distinct backers
Active since
2023-02
latest 2025-03
Funding by year
EUR raised per yearMaxion Therapeutics — funding by year — interactive chart.
Data table
| Maxion Therapeutics — funding by year | |
|---|---|
| 2023 | €17M |
| 2025 | €66M |
Signals
High confidenceRaise-next likelihood70
base rate 44% for Series A
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood11
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-03-17 | Series A | €66M | BGF,British Patient Capital,Eli lilly and company,General Catalyst,LifeArc Ventures,Monograph Capital+1 more | View deal → |
| 2023-04-19 | Grant | €2.3M | Innovate UK | View deal → |
| 2023-02-16 | Series A | €15M | BGF,LifeArc Ventures,Monograph Capital | View deal → |
Investors
8Related news
- Maxion Therapeutics scoops £2m Innovate UK grantuktech.news · 2023-04
- Biotech Maxion Therapeutics secures £13m from investorsuktech.news · 2023-02
- tech.eu
Similar companies
same sector or countryGlobal coverage: FundingData